Magnova 500mg/62.5mg Injection
Marketer
Lupin Ltd
Salt Composition
Cefepime (500mg) + Tazobactum (62.5mg)
Overview Magnova 500mg/62.5mg Injection
Combiflox 500 mg/62.5 mg Injection, a dual-antibiotic formulation, combats diverse bacterial infections by inhibiting microbial proliferation. Administration must be strictly under a healthcare provider's guidance. Consistent adherence to the prescribed schedule is crucial; complete the entire course regardless of symptom improvement. Typical side effects include nausea, vomiting, diarrhea, and skin rashes. Injection site reactions (redness, swelling, pain) may occur but usually resolve spontaneously. Report any worsening side effects immediately to your physician. Seek immediate medical attention for allergic reactions (rash, itching, swelling, respiratory distress). Inform your doctor of all current medications, including those for pre-existing conditions, before commencing treatment. Pregnant or lactating individuals require prior medical consultation. Alcohol consumption should be avoided due to potential additive drowsiness. While generally non-impairing to driving ability, refrain from operating vehicles if drowsiness or dizziness develops.
Uses of Magnova 500mg/62.5mg Injection
Infections caused by bacteria
Major Benefits of Magnova 500mg/62.5mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Magnova 500mg/62.5mg Injection:
- Diarrhea
- Increased white blood cell count (eosinophils)
- Injection site phlebitis
- Skin rash
- Increased liver enzymes
- Positive Coombs test
How to use Magnova 500mg/62.5mg Injection:
The medication will be administered by your healthcare provider; self-medication is strongly discouraged.
How Magnova 500mg/62.5mg Injection works:
Magnova Injection, containing 500 mg Cefepime and 62.5 mg Tazobactum, combines an antibiotic with a beta-lactamase inhibitor. Cefepime's antibacterial action stems from its disruption of bacterial cell wall synthesis, crucial for bacterial viability. Tazobactum counteracts bacterial enzymes that would otherwise degrade Cefepime, thus broadening Cefepime's effectiveness and overcoming bacterial resistance.
SAFETY ADVICE
AlcoholCAUTION
Use of alcohol with Magnova 500 mg/62.5 mg Injection requires careful consideration. Seek medical advice before combining them.
PregnancySAFE IF PRESCRIBED
The injectable medication Magnova 500 mg/62.5 mg is typically deemed safe for use during gestation. Preclinical trials in animals revealed minimal or no harmful consequences for fetal development; clinical data from human subjects, however, remain scarce.
Breast feedingSAFE IF PRESCRIBED
Magnova 500 mg/62.5 mg Injection poses no known breastfeeding risks. Research in humans indicates minimal drug transfer to breast milk, presenting no apparent danger to the infant.
DrivingUNSAFE
Following administration of Magnova 500 mg/62.5 mg Injection, temporary blurred vision may occur. Refrain from driving until visual acuity returns to normal.
KidneyCAUTION
Patients with kidney impairment should use Magnova 500 mg/62.5 mg Injection judiciously. Dosage modifications for Magnova 500 mg/62.5 mg Injection may be necessary. Physician consultation is advised.
LiverSAFE IF PRESCRIBED
Magnova 500 mg/62.5 mg Injection appears safe for individuals with hepatic impairment. Current evidence indicates dose modification may be unnecessary; however, physician consultation is advised.
What if you forget to take Magnova 500mg/62.5mg Injection :
Omit a Magnova 500 mg/62.5 mg Injection dose? Seek medical advice immediately.
Facts to Know About Magnova 500mg/62.5mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Antimicrobials |
3,018 People bought this recently